14 results about "Locked nucleic acid" patented technology

The present application relates to the field of biotechnology and molecular detection, in particular to a plant and pathogenic bacteria interaction gene expression analysis method based on UMI tag, comprising: obtaining interaction sample total nucleic acid extract; and constructing a molecular hybridization system with host-specific chimeric blocking probes containing locked nucleic acid modification and 3' end dideoxy modification, and reverse transcription primers; through temperature rising and denaturation and temperature reduction and annealing, the blocking probes are combined with host high abundance nucleic acid to form a hybridization blocking complex, and the primers are combined with pathogenic bacteria nucleic acid; template switching oligonucleotides with unique molecular identifier sequences and reverse transcriptase are added, the host extension is blocked, and UMI is introduced into the pathogenic bacteria complementary chain, and an interaction expression library is generated; after sequencing, the pathogenic bacteria effective reads and the host invalid reads are counted, and the effective interaction signal signal-to-noise ratio is output; the present application can preferentially capture pathogenic bacteria transcripts in the high background of host RNA.

Disclosed herein include systems, methods, compositions, and kits for prevention of antibody oligonucleotide extension. There are provided, in some embodiments, blocking oligonucleotides. In some embodiments, the blocking oligonucleotide comprises a binding region capable of hybridizing barcoding oligonucleotides to form a protected duplex. The blocking oligonucleotide can be a locked nucleic acid (LNA), a peptide nucleic acid (PNA), a DNA, an LNA / PNA chimera, an LNA / DNA chimera, or a PNA / DNA chimera. In some embodiments, the 3′ end of a blocking oligonucleotide is incapable of being extended by a reverse transcriptase or a polymerase. In some embodiments, the blocking oligonucleotide of a protected duplex is incapable of being removed by the strand displacement activity of a reverse transcriptase or a polymerase.

The application discloses a method for detecting thyroid cancer driving gene mutations based on multiplex fluorescence PCR, and belongs to the technical field of molecular biology detection. The method simultaneously detects nine mutation sites, namely BRAF V600E, NRAS Q61R, NRAS Q61K, HRAS Q61R, HRAS Q61K, KRAS G12V, KRAS G12D, TERT C228T and TERT C250T in a single tube reaction. The method enhances the distinguishing ability of wild type and mutant types by using a locked nucleic acid modified allele-specific primer, suppresses wild type amplification by using a peptide nucleic acid clamp, introduces a competitive internal reference probe to correct amplification efficiency difference, and reduces the sample usage to one fifth of that of a traditional multi-tube scheme. The mutation detection lower limit reaches 0.5% allele frequency, and the total time consumption is not more than 2.5 h.

The present application relates to the technical field of biological detection, and a double-path apple codling moth identification system integrating RPA-LFS rapid screening and TaqMan qPCR real-time quantification, a locked nucleic acid probe primer set, a kit and a method thereof. COI Through gene screening and primer screening, the present application designs recombinase-mediated isothermal amplification (RPA) and TaqMan qPCR primers and probes for the barcode of the cytochrome oxidase subunit I (COI) gene of apple codling moth, and establishes an RPA-LFS method in combination with immunolateral flow. The RPA-LFS method can complete amplification and visual judgment within 20 minutes at 39 DEG C, and is suitable for on-site rapid detection. The TaqMan qPCR method can realize high-sensitivity quantitative analysis under the condition of crude extract. Through double-path complementary design, the consistency of the results of on-site screening and laboratory confirmation detection is realized, and the method is simple to operate and suitable for pest quarantine at ports, epidemic monitoring in agricultural production areas and quarantine at storage and transportation links.

A computer-implemented framework for designing high-efficiency and high-specificity nucleic acid molecules targeting transfer RNA (tRNA) and its derivatives (tDRs). The framework comprises two primary algorithms. The first, tBOND-G, designs guide RNAs (gRNAs) for Cas13-mediated tRNA cleavage by calculating physical parameters, including target site accessibility and binding energy, and processing them through a Support Vector Machine (SVM) model to predict cleavage efficiency. The second algorithm, tBOND-L, designs therapeutic Locked Nucleic Acid-modified antisense oligonucleotides (LNA-ASOs) that specifically target a tDR without binding to its parent tRNA. This method utilizes a processor to derive an efficiency score based on relative binding affinity and a specificity score based on simulated competitive binding environments.

The present invention relates to RNA molecules and, in particular, but not exclusively, to methods of making RNA molecules, and methods of translating RNA molecules into proteins. The present invention relates to improved methods of forming UNA-RNA by in vitro transcription, and the resulting RNA molecules. Furthermore, the present invention relates to novel methods of enhancing the expression and / or translation of RNA, i.e. protein expression, and methods for improving the stability of RNA molecules. The present invention also relates to reducing the activation of innate sensing, interferon production, and / or degradation of RNA molecules in a host. The present invention also relates to the use of said RNA molecules in vaccines and other therapeutic pharmaceutical compositions, and their use in immunization and therapy, such as RNAi, gene therapy, gene editing and protein replacement. In particular, the present invention relates to locked nucleotide and locked nucleic acid (LNA)-RNA molecules, and the use or incorporation of such locked nucleotide and LNA-RNA molecules in any of the above mentioned applications.

The present application relates to the field of nucleic acid detection, and particularly relates to a novel nucleic acid detection method based on CRISPR-Cas12. By introducing chemical modification (such as locked nucleic acid modification), the present application constructs a method for site-specific cleavage of specific phosphodiester bonds in single-stranded nucleic acid by Cas protein containing RuvC domain and a method for detecting target DNA in a sample to be tested, so as to realize site-specific cleavage and trigger signal cascade amplification, and then realize rapid and high-sensitivity detection of nucleic acid.

This invention discloses a nicked oligonucleotide (ASO) and a pharmaceutical composition comprising the nicked oligonucleotide, wherein the nicked oligonucleotide compound specifically inhibits IL-1β eRNA transcription and wherein the nicked oligonucleotide comprises about 14 to about 25 nucleotide bases, having a (3' to 5') 3' wing region containing 3 to 7 chemically modified RNA bases, an interstitial region containing at least 8 DNA bases, and a 5' wing region containing 3 to 7 chemically modified RNA bases, and wherein the nicked oligonucleotide is substantially complementary to the 14-25 base region on the IL-1β eRNA (SEQ ID NO. 1). Preferably, each nicked oligonucleotide is linked by a phosphate thioester (P=S) nucleotide internucleotide bond that runs through the nicked oligonucleotide; and wherein the modified nucleotide bases are selected from the group consisting of 2'-methoxyethyl (MOE) nucleotides, locked nucleic acid nucleotides (LNA), and combinations thereof.

The present disclosure provides methods and compositions of modified oligonucleotide primer and probe combinations, structurally modified with locked nucleic acids, quenchers, and dyes, effective to detect tumor-derived Human Papilloma Virus (HPV) and tumor-derived Epstein-Barr virus (EBV) and, especially, to distinguish viral DNA derived from tumors from viral DNA derived from infectious viral particles.

This invention discloses a buffer solution for locked nucleic acid probe-based real-time quantitative PCR (RT-PCR). The buffer solution is composed of dithiothreitol, betaine, tetramethylammonium chloride, ammonium sulfate, tris(hydroxymethyl)aminomethane, magnesium chloride, a Tween-20 / glycerol mixture, and bovine serum albumin. The pH of the buffer solution is 7.0–9.0. The volume ratio of Tween-20 to glycerol in the Tween-20 / glycerol mixture is 1:80–120. By adding protective agents and promoters, adjusting the pH value, and adjusting the concentration of corresponding components, this buffer solution effectively protects the enzymes necessary for real-time quantitative PCR detection and improves the stability of modified probes in RTS. It is superior to other solutions for locked nucleic acid modified probes in RTS, improving detection sensitivity, fluorescence intensity, and result reliability. Therefore, this buffer solution has broad application prospects in detections requiring more stringent and precise data.

Provided herein are methods and compositions for reducing the expression and / or activity of an oncogenic transfer RNA (tRNA). Composition for treating cancer in the subject are disclosed, comprising an inhibitor of an oncogenic transfer RNA (tRNA) to a subject in need thereof, wherein the oncogenic tRNA comprises an inhibitory nucleic acid such as ARG-TCT-4-1, an siRNA, an shRNA, an miRNA, an antisense oligonucleotide, or a nucleic acid modification such as a locked nucleic acid, a phosphorothioate modification, a 2′—O-methyl modification, a 2′—O-methoxyethyl modification, a 2′-fluoro modification, a phosphorodiamidate modification, or a mesylphosphoramidate modification. The disclosed compositions are disclosed as treating cancers such as a sarcoma, a glioblastoma, an adrenocortical carcinoma, a cholangiocarcinonma, a melanoma, a glioma, a diffuse glioma, a mature B cell neoplasm, a non-small cell lung cancer, an esophagogastric adenocarcinoma, a pheochromocytoma, a hepatocellular carcinoma, an endometrial carcinoma, a pancreatic adenocarcinoma, a breast carcinoma, an invasive breast carcinoma, a head and neck squamous cell carcinoma, a bladder urothelial carcinoma, a colorectal adenocarcinoma, an ovarian epithelial tumor, a prostate adenocarcinoma, a cervical squamous cell carcinoma, a renal non-clear cell carcinoma, or a renal clear cell carcinoma.

The invention relates to double stranded nucleic acids of formula (I), in particular, conjugated double stranded nucleic acids comprising at least one or two LNA (= locked nucleic acid) modification(s) in one or two defined positions of the sense strand. Such (conjugated) nucleic acids can be used to inhibit expression of a target gene. The invention further relates to compositions comprising said (conjugated) nucleic acids for use in the prophylaxis or treatment of a disease.

The application relates to a primer and a locked nucleic acid probe group for real-time fluorescent quantitative PCR detection of two strong and weak strains of goose parvovirus, wherein the strong and weak strains of goose parvovirus include MDGPV strong and weak viruses and SBDSV strong and weak viruses, and the sequences of the primer and the locked nucleic acid probe group are shown in SEQ ID NO. 1-8. The LNA-TaqMan real-time fluorescent quantitative PCR detection method established by using the primer and the LNA-TaqMan probe group can simultaneously detect, differentially diagnose and accurately quantify the strong and weak strains of goose parvovirus (duck small goose plague virus and / or duck short-beak dwarf syndrome virus strong and weak viruses), and is high in sensitivity, strong in specificity and good in repeatability.